| Summary: | Dupliumab (Dupixent) is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The recommended dose of dupilumab is age- and weight-specific. In adolescents 12 to 17 years old who weigh < 60 kg, two subcutaneous injections of 200 mg of DUP should be administered as the loading dose during the first week, after which one 200 mg injection should be taken every other week. In adolescents who weigh ≥ 60 kg, and in all adults (≥ 18 years), the recommended loading dose is 600 mg of DUP (two 300 mg injections), followed by 300 mg every other week. At the submitted price of $959.94 for each of the 200 mg and 300 mg injections, the first-year cost of DUP is $25,918 per patient and the annual maintenance cost is $24,958 per patient. In the model, the sponsor assumed DUP treatment dosage was 200 mg (for adolescents < 60 kg) or 300 mg (for adolescents ≥ 60 kg and adults) every two weeks. No cost was associated with the use of topical therapy in the model. The clinical outcomes of interest were QALYs and life-years. The economic analysis was undertaken over a lifetime time horizon (86 years) from the perspective of the public health care payer. A discount of 1.5% per annum was applied to both costs and outcomes
|
|---|